Bioness Medical Strengthens Neurorehabilitation with PoNS® Acquisition

Bioness Medical, Inc., a pioneer in the field of rehabilitation technologies, has made a significant move by acquiring the Portable Neuromodulation Stimulator (PoNS®) System. This strategic acquisition enhances Bioness's offerings in neurorehabilitation, particularly for patients dealing with gait and balance disorders caused by neurological conditions.

Expanding Capabilities

For almost two decades, Bioness Medical has been at the forefront of functional electrical stimulation (FES) technology, assisting recovery for individuals affected by stroke, traumatic brain injuries, multiple sclerosis, and other neurological disorders. The addition of the PoNS System marks a watershed moment as it introduces non-invasive central neuromodulation into their portfolio. This technology operates by stimulating cranial nerve pathways via the tongue, aiming to boost neuroplasticity and facilitate functional recovery.

The PoNS System has demonstrated promising outcomes in clinical studies, where patients with chronic neurological issues have shown marked improvements in gait and balance as part of specialized rehabilitation programs. This supports Bioness’s ambition to offer comprehensive solutions for rehabilitation.

Insights from Leadership

"PoNS technology represents a differentiated approach to neuromodulation that complements our core FES platform," stated Todd Cushman, CEO of Bioness Medical. This acquisition not only diversifies Bioness's technology but also enhances its relationships with rehabilitation providers developed over their extensive history in the sector. With the addition of PoNS, they are set to offer clinicians an innovative, non-invasive therapy that could significantly improve patient rehabilitation outcomes.

A Unified Rehabilitation Approach

By integrating the PoNS System with its existing product lineup—which includes services such as L300 Go®, H200® Wireless, and the Vector® Gait Safety System—Bioness is pioneering a multi-modal therapy platform. This unique combination allows healthcare professionals to address both peripheral motor activation and central neural network modulation seamlessly. Such integration can revolutionize how rehabilitation is conducted, offering targeted solutions that improve outcomes for patients.

Fostering Growth in Neurorehabilitation

The acquisition of the PoNS System is not only a technological enhancement but also one that amplifies Bioness Medical's research and development potential. This strategic move supports enhanced clinical programs that may integrate FES and neuromodulation therapies—a combination designed to maximize patient recovery. Moreover, it positions Bioness to tap into the burgeoning sectors of neuromodulation and neurorehabilitation, paving the way for expansion within clinical and commercial avenues.

As the third acquisition since becoming an independent entity on December 31, 2024, following its acquisition by Accelmed Partners, Bioness Medical is dedicated to growth through targeted initiatives and continual innovation.

About Bioness Medical, Inc.

Bioness Medical stands as a leader in providing advanced rehabilitation technologies aimed at restoring mobility, function, and independence to patients. Its comprehensive portfolio includes functional electrical stimulation, robotic gait training, and neuromodulation solutions—supporting healthcare systems and clinicians across the globe with cutting-edge, evidence-based treatments. The continued commitment of Bioness Medical to innovate emphasizes its role as a cornerstone in the neurorehabilitation landscape.